Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform ...